Purpose: This work aimed at investigating demographic, clinical, and genetic characteristics of individuals experiencing their first familial Mediterranean fever (FMF) attack at age ≥ 40 years in a very large cohort of Armenian FMF patients.
INTRODUCTION
Familial Mediterranean fever (FMF) is an autosomal recessive inherited autoinflammatory disorder that is characterized by recurrent febrile episodes, accompanied by pain in the abdomen (peritonitis), chest (pleuritis), or joints (arthritis), and erysipelas-like skin erythema. 1 The disease is observed primarily in Armenians, Turks, Arabs, and North African Jews. 2 FMF is caused by several mutations within the Mediterranean fever (MEFV) gene, which is localized on chromosome 16p13.3. This gene is composed of 10 exons, which encode a 781-amino acid protein known as pyrin. 3, 4 Four (M694V, M694I, M680I, V726A) and one (E148Q) missense mutations in exon 10 and exon 2, respectively, are the most frequently reported MEVF variants in ethnic groups at risk of FMF. 3, 5, 6 With an estimated 20%, the overall MEFV carrier rate in the Armenian population is extremely high, resulting in an FMF prevalence of approximately 3%. 7, 8 In general, FMF diagnosis is based on clinical findings, which can be backed up but never replaced by genetic testing. 9 Moreover, diagnosing FMF may be extremely difficult in individuals with nonspecific symptoms, with late-onset disease, or with an absence of family history. In such cases, mutational analysis is crucial to enable an early diagnosis. 10, 11 The age of onset of FMF varies with about 60 and 90% of patients experiencing their first attack before the age of 10 and 20 years, respectively. 12 Hence, FMF with the first attack occurring at the age of ≥ 40 years is rare and only a few small studies have investigated the clinical and molecular genetic characteristics of FMF patients with late-onset disease. [12] [13] [14] [15] Therefore, the present study was conducted to better define the subset of late-onset disease in 10,370 Armenian FMF patients by matching MEFV mutational spectra and resulting genotypes against the clinicodemographic profiles collected for these patients between 2005 and 2016.
MATERIALS AND METHODS

Ethical approval
The study was approved by the local ethics committee of the Yerevan State Medical University, Yerevan, Armenia, and is in accordance with the latest version of the Declaration of Helsinki. All patients provided written informed consent. 1 
FMF patients
A cohort of 10,370 Armenian patients diagnosed with FMF based on the Tel Hashomer criteria and carrying at least one MEFV mutant allele who visited the Center of Medical Genetics and Primary Health Care in Yerevan between 2005 and 2016 were included in this study. Personal and medical data, including age, sex, age of disease onset, fever, abdominal pain (peritonitis), chest pain (pleuritis), arthritis, skin involvement (erysipelas-like erythema), proteinuria, and amyloidosis were recorded. Disease severity was determined by the use of a scoring system suggested by Pras et al. 16 Patients also suffering from non-FMF-related inflammation or chronic disease were excluded from the study.
MEFV mutational analysis DNA was isolated from anticoagulated blood using the GenXtract DNA extraction system (ViennaLab Diagnostics, Vienna, Austria). Twelve common MEFV mutations including E148Q (c.442G > C) in exon 2; P369S (c.1105C > T) in exon 3; F479L (c.1437C > G) in exon 5; and M680I G/C (c.2040G
and R761H (c.2282G > A; RefSeq NG_007871.1) in exon 10 were simultaneously analyzed using a test strip-based reverse-hybridization assay (FMF StripAssay, ViennaLab Diagnostics). The operators were blinded to the patient's disease status.
Statistical analysis
For subgroup comparison of categorical variables, the chisquare test (n × k 
RESULTS
Baseline characteristics
In total, 10,370 individuals with a clinical diagnosis of FMF were included, of whom 4,881 were female (47.10%), and 5,489 (52.90%) were male. The mean age was 27.91 ± 15.98 years. Of all participants, 3,520 (33.90%) could be identified with a family history of FMF. Concerning the age of disease onset, 10,016 (96.60%) and 354 (3.40%) patients experienced their first attack before the age of 40 years and at or after the age of 40 years (i.e., late-onset FMF), respectively. MEFV mutational spectrum and genotypes Table 2) . The mutational spectrum obtained for 10,016 (96.60%) and 354 (3.40%) FMF patients with an age of onset o40 and ≥ 40 years is illustrated in Table 3 . Genotypes M680I/E148Q (P = 0.004), M694V/E148Q (P o 0.001), and V726A/V726A (P o 0.001) were significantly associated with the late-onset variant whereas genotypes M694V/M694V (P o 0.001), V726A/F479L (P = 0.005), and V726A/M680I (P = 0.023) were more frequently observed in patients with a disease onset o40 years. Of note, 12/354 (3.39%) patients with lateonset FMF were found to be homozygous for the M694V mutation.
As listed in
Clinical aspects of the late-onset disease
The demographic aspects and clinical manifestations of FMF patients with age of onset o40 and ≥ 40 years are presented in Table 4 . In the late-onset FMF group (n = 354) the mean age (female, 194 (54.80%); male, 160 (45.20%)) was 56.97 ± 7.82 years. For those patients with a disease onset before 40 years of age the mean age at onset of disease was 11.86 ± 9.66 years.
The frequencies of FMF-related clinical manifestations were significantly different between the two groups except for arthritis, proteinuria, and amyloidosis. Patients with disease onset ≥ 40 years of age showed a milder disease phenotype (P o 0.001) presenting significantly less frequent fever (89.55 vs. 92.46%, P = 0.048), skin manifestation (9.89 vs. 14.99%, P = 0.009), and chest pain (43.22 vs. 48.66%, P = 0.046) compared to individuals with a disease onset before 40 years of age. However, abdominal pain was significantly more frequent in patients with late-onset disease (90.40 vs. 86.42%, P = 0.035).
DISCUSSION
In this study, MEFV mutational spectra and resulting genotypes were matched against the clinicodemographic profiles of 10,370 FMF patients including 354 (3.40%) individuals with late-onset disease. The most frequently observed mutations were M694V (41.34%), V726A (27.62%), and M680I (18.18%), whereas all other mutations were found with distinctly lower frequencies. These findings are in line with two earlier Armenian studies that observed M694V (50.60 and 56.10%), V726A (22.30 and 17.90%), and M680I (18.70 and 17.90%) to be most common including 3,000 and 1,299 FMF patients, respectively. 7, 17 With respect to the genotype distribution among FMF patients, we found the following genotypes to be most frequent: M694V/V726A (20.22%), M694V/-(12.02%), M680I/V726A (11.72%), M694V/M694V (11.12%), M694V/ M680I (10.19%), V726A/-(5.47%), and M694V/E148Q (3.74%). In contrast, a previous Armenian study comprising 3,000 FMF patients found a divergent order: M694V/M694V (20.90%), M694V/V726A (18.00%), M694V/M680I (12.70%), 20%) ). An earlier study on late-onset FMF in 00%) ). While amyloidosis has been described in patients with a disease onset after age 40, 15 this is, to the best of our knowledge, the first report on M694V homozygosity in lateonset FMF patients. This finding is of special interest because several studies have associated M694V homozygosity with an earlier age of onset and a more severe disease phenotype. [17] [18] [19] [20] [21] [22] [23] Corroborating previous data, 12 none of our late-onset FMF patients carried the complex allele V726A-E148Q, which is known to be present in individuals with a severe disease phenotype. 22, 23 In the current study, genotypes M680I/E148Q (P = 0.004), M694V/E148Q (P o 0.001), and V726A/V726A (Po 0.001) were significantly associated with the late-onset variant. While genotypes M694V/E148Q and V726A/V726A have already been described in FMF patients with late-onset and/or milder disease, 12, 23 this is the first report to correlate genotype M680I/ E148Q with the late-onset variant, supporting the observation that both mutations M680I and E148Q associate with a less severe disease activity. 7, 12, 23 Furthermore, mutation E148Q has been shown to predispose to a prolonged disease onset. 17 Small study populations comprising small percentages of late-onset patients only are the major limitations of studies published so far. [12] [13] [14] [15] For example, based on their findings in 20 late-onset FMF patients Tamir et al. 12 suggested a milder disease course without proteinuria and amyloidosis presenting significantly less arthritis, chest pain, fever, and skin manifestations and a nonsignificant difference in abdominal pain compared to patients with an age of onset before 40 years of age.
The results of this study support the concept of late-onset FMF as being a less symptomatic disease variant. Patients with an age of onset before 40 years had significantly more frequent fever (P = 0.048), skin involvement (P = 0.009), chest pain (P = 0.046), and a more severe disease phenotype (P o 0.001) compared to the group of patients with an age of onset ≥ 40 years. Interestingly, abdominal pain was found more often in the late-onset FMF group (P = 0.035), whereas arthritis, proteinuria, and amyloidosis did not differ significantly between the two groups.
The main strength of this retrospective study is its sample size, which enables the clinical and genetic characterization of 354 patients with late-onset FMF. However, it is limited by the fact that genetic analysis was performed for the 12 most common MEFV mutations only, thus neglecting less frequent ones. Another limitation of this work is the lack of information regarding response and compliance to colchicine treatment.
Our data suggest that late-onset FMF is more prevalent in women and is of greater clinical as well as genetic heterogeneity than previously reported. Therefore physicians should include FMF in their differential diagnosis list even when evaluating older patients with a relevant ethnic background. Moreover, further studies including late-onset FMF patients homozygous for MEFV mutation M694V may lead to the identification of novel disease-modifying mechanisms.
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